| Active Not Recruiting | A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Pro NCT07155499 | AO GENERIUM | Phase 1 / Phase 2 |
| Completed | Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Stu NCT05960266 | University of Zurich | EARLY_Phase 1 |
| Completed | Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract NCT05297760 | University of Zurich | Phase 1 / Phase 2 |
| Completed | An Exploratory Study of PQ Grass 27600 SU NCT04687059 | Allergy Therapeutics | Phase 2 / Phase 3 |
| Completed | Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. NCT04622917 | Karolinska Institutet | Phase 4 |
| Completed | Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms NCT03772405 | Fraunhofer-Institute of Toxicology and Experimental Medicine | N/A |
| Completed | Short and Mid-term Repeatability of Active Anterior Rhinomanometry (AAR) Measurements in Paediatric Age NCT03286049 | Istituto per la Ricerca e l'Innovazione Biomedica | — |
| Completed | A Dose-finding Study of ASP4070 NCT03101267 | Astellas Pharma Inc | Phase 2 |
| Completed | Intralymphatic Immunotherapy in Increasing Doses, Substudy NCT02975479 | Karolinska Institutet | Phase 2 / Phase 3 |
| Completed | Drug Utilization Study for Pirinase Hayfever Relief NCT02856282 | GlaxoSmithKline | — |
| Completed | Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or NCT02478398 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Untersuchung Zur Erfassung Und Kontrolle Der Lebensqualität Unter Einer Therapie Mit Pollinex Quattro Bei Heus NCT03014661 | Universität des Saarlandes | — |
| Completed | Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induce NCT02256553 | ALK-Abelló A/S | Phase 4 |
| Completed | Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis (Hay Fever) NCT01699165 | University of Aarhus | N/A |
| Completed | Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever NCT01500629 | McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. | EARLY_Phase 1 |
| Completed | An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy V NCT01480271 | GlaxoSmithKline | Phase 1 |
| Completed | The Effects of Immunotherapy in the Nose NCT01985542 | Helsinki University Central Hospital | N/A |
| Withdrawn | Study of AHIST in Seasonal Allergic Rhinitis Patients NCT01008397 | Magna Pharmaceuticals, Inc. | Phase 1 |
| Completed | Long-Term Effects of Sublingual Grass Therapy NCT01335139 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal All NCT01279057 | Sandoz | Phase 3 |
| Completed | Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olop NCT01258309 | Allergan | Phase 3 |
| Terminated | Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on NCT01337323 | GlaxoSmithKline | — |
| Unknown | Optimal Concentration of Dermatophagoides Pteronyssinus (Dp) Allergen Extract for Skin Prick Test (SPT) of Tha NCT01172613 | Siriraj Hospital | — |
| Completed | A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Sympt NCT01038427 | Sandoz | Phase 3 |
| Completed | Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients NCT00932256 | Magna Pharmaceuticals, Inc. | Phase 1 |
| Completed | Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Effic NCT01007721 | Boehringer Ingelheim | Phase 2 |
| Completed | 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover NCT00972504 | GlaxoSmithKline | Phase 2 |
| Completed | Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equival NCT00917488 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Safety and Tolerability Study of Ragweed SLIT Tablets NCT01224834 | Stallergenes Greer | Phase 1 |
| Completed | Study of rBet v1 Tablets NCT00901914 | Stallergenes Greer | Phase 2 |
| Completed | Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo NCT00851344 | GlaxoSmithKline | Phase 2 |
| Completed | Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Unit NCT00718744 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLET NCT00762983 | Merck Sharp & Dohme LLC | — |
| Completed | Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P056 NCT00761527 | Organon and Co | — |
| Completed | A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allerg NCT00612118 | GlaxoSmithKline | Phase 2 |
| Completed | A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic NCT00612820 | GlaxoSmithKline | Phase 2 |
| Completed | Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subje NCT00694993 | GlaxoSmithKline | Phase 1 |
| Completed | Safety and Tolerability Study of rBet v1 SLIT Tablets NCT00889460 | Stallergenes Greer | Phase 1 |
| Completed | Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects NCT00605852 | GlaxoSmithKline | Phase 1 |
| Completed | An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposur NCT00537355 | Dynavax Technologies Corporation | Phase 2 |
| Completed | Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense NCT00501527 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine NCT00502775 | GlaxoSmithKline | Phase 4 |
| Completed | Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent NCT00807053 | AstraZeneca | Phase 2 |
| Completed | A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis NCT00464568 | GlaxoSmithKline | Phase 2 |
| Completed | Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber NCT00430157 | GlaxoSmithKline | Phase 2 |
| Completed | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine NCT00435461 | GlaxoSmithKline | Phase 4 |
| Completed | Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 NCT00396149 | Stallergenes Greer | Phase 1 |
| Completed | A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-4 NCT00384475 | AstraZeneca | Phase 3 |
| Completed | Twin SUBLIVAC® Grasses Clinical Efficacy Study NCT00422149 | HAL Allergy | Phase 3 |
| Completed | Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683) NCT00406783 | Organon and Co | Phase 3 |
| Completed | Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) NCT00295022 | UCB S.A. - Pharma Sector | Phase 4 |
| Completed | Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Expose NCT00315523 | UCB Pharma | Phase 3 |
| Terminated | Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults NCT00387738 | Dynavax Technologies Corporation | Phase 2 |
| Terminated | Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug NCT00318747 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Probiotics for Birch Pollen Allergy NCT00746226 | Danisco | Phase 1 / Phase 2 |
| Completed | Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber NCT00377728 | GlaxoSmithKline | Phase 2 |
| Completed | Investigate Two Trial Models; Vienna Challenge Chamber (in and Out of Season) and Park Study (in Season) Using NCT00400998 | Research Consult GmbH | Phase 2 |
| Completed | Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis ( NCT00319995 | Organon and Co | Phase 3 |
| Completed | The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subject NCT00276016 | Organon and Co | Phase 3 |
| Completed | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR) NCT00197262 | GlaxoSmithKline | Phase 3 |
| Completed | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis NCT00115089 | Rigel Pharmaceuticals | Phase 2 |
| Completed | Study Of Perennial Allergic Rhinitis NCT00358475 | GlaxoSmithKline | Phase 3 |
| Completed | Study In Adults And Adolescents With Seasonal Allergic Rhinitis. NCT00225823 | GlaxoSmithKline | Phase 3 |
| Completed | Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Ons NCT00118729 | GlaxoSmithKline | Phase 3 |
| Completed | Nasal Ocular Reflexes Contribute to Eye Symptoms NCT00117832 | University of Chicago | N/A |
| Completed | Study of GW685698X In Patients With Seasonal Allergic Rhinitis NCT00363740 | GlaxoSmithKline | Phase 3 |
| Completed | Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a N NCT00659503 | AstraZeneca | Phase 3 |
| Completed | Study In Adults And Adolescents With Seasonal Allergic Rhinitis NCT00115622 | GlaxoSmithKline | Phase 3 |
| Completed | Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as NCT00659594 | AstraZeneca | Phase 3 |
| Completed | An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) NCT00127647 | Organon and Co | Phase 3 |
| Completed | Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensit NCT00544388 | UCB Pharma | Phase 3 |
| Completed | Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects NCT00521040 | UCB Pharma | N/A |
| Completed | To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allerg NCT00659841 | AstraZeneca | Phase 3 |
| Completed | Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Withou NCT00805324 | Organon and Co | Phase 3 |
| Completed | Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442 NCT00805584 | Organon and Co | Phase 4 |
| Completed | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P0 NCT00070707 | Organon and Co | Phase 4 |
| Completed | An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269) NCT00092885 | Organon and Co | Phase 3 |
| Completed | Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults NCT00839189 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever NCT00135629 | Imperial College London | Phase 3 |
| Completed | Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis NCT00542607 | UCB Pharma | Phase 4 |
| Completed | Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of NCT02932774 | Johnson & Johnson Consumer and Personal Products Worldwide | Phase 4 |
| Completed | Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6 NCT03879772 | Organon and Co | Phase 3 |
| Completed | Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma NCT00135642 | Imperial College London | Phase 3 |
| Completed | Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhini NCT03882047 | Organon and Co | Phase 3 |
| Completed | Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Aller NCT03861559 | Organon and Co | Phase 3 |